Foghorn Therapeutics (FHTX) Accounts Payables (2019 - 2026)

Foghorn Therapeutics' Accounts Payables history runs 8 years deep, the most recent figure standing at $3.3 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 18.48% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at $3.3 million (down 18.48% YoY), while the FY2025 annual figure was $4.3 million, up 12.71% from the prior year.
• Accounts Payables for Q1 2026 stood at $3.3 million, down from $4.3 million in the prior quarter.
• The five-year high for Accounts Payables was $7.3 million in Q1 2023, with the low at $3.2 million in Q3 2025.
• The 5-year median for Accounts Payables is $4.8 million (2024), against an average of $4.8 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables jumped 90.73% in 2023, then plunged 46.88% in 2024.
• Foghorn Therapeutics' Accounts Payables stood at $5.4 million in 2022, then rose by 15.63% to $6.3 million in 2023, then slumped by 39.54% to $3.8 million in 2024, then climbed by 12.71% to $4.3 million in 2025, then dropped by 22.25% to $3.3 million in 2026.
• Business Quant data shows FHTX's Accounts Payables at $3.3 million in Q1 2026, $4.3 million in Q4 2025, and $3.2 million in Q3 2025.